Open Access Open Access  Restricted Access Subscription or Fee Access

Integrating Network Pharmacology And Molecular Docking To Investigate The Possibility Of Rutin Against Gout

Haritha P M

Abstract


Objective: Gout is an arthritic condition resulting from the deposition of monosodium urate crystals in and around the joints. Rutin, a bioflavanoid or a plant pigment that is mainly found in vegetables and fruits.It is widely known for its anti-inflammatory and antioxidant activity.Hence this research paper proposes the use of an integrated approach of network pharmacology and molecular docking to investigate the potential of Rutin as a treatment option for gout.

Methods: In the current study, computational methods like network pharmacology and molecular docking were carried out for the analysis.  IMPPAT was the database used to retrieve the rutin analogues and network based analysis was utilized to understand the interaction between the structure based predicted targets and the know target for the illness obtained from GeneCards. For the interpretation of biological process involved by the targets, Gene ontology pathway analysis was carried out. PyRx, a virtual tool is used for understanding the binding affinity between the targets and the analogues and for visualizing the interaction between the structures was done using BIOVIA discovery studio software. Pharmacological studies were done on the basis of ADMET analysis.

Results: The result from this study showed that Rutin has the ability to inhibit the action of Xanthine oxidase, major enzyme involved in the production of uric acid. But pharmacological analysis done on the Rutin analogue showed variation in the results.

Conclusion: The current study demonstrated that Rutin has a role in treating gout but further studies need to be done on Rutin analogues to understand their pharmacological action on the disease.


Keywords


Gout, Rutin, Network pharmacology, Molecular docking, BIOVIA, ADMET screening

Full Text:

PDF

References


Kapoor B, Kaur G, Gupta M, Gupta R. Indian medicinal plants useful in treatment of gout: a review for current status and future prospective. Asian J Pharm Clin Res. 2017;10(11):407-16.

So A. Developments in the scientific and clinical understanding of gout. Arthritis research & therapy. 2008 Oct;10(5):1-6.

Roddy E, Doherty M. Gout. Epidemiology of gout. Arthritis research & therapy. 2010 Dec;12:1-1.

Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Research & Therapy. 2006 Apr;8:1-7.

Scanu A, Luisetto R, Ramonda R, Spinella P, Sfriso P, Galozzi P, Oliviero F. Anti-Inflammatory and Hypouricemic Effect of Bioactive Compounds: Molecular Evidence and Potential Application in the Management of Gout. Current Issues in Molecular Biology. 2022 Oct 25;44(11):5173-90.

Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, Stamp LK. Gout. Nat Rev Dis Primers. 2019 Sep 26;5(1):69. doi: 10.1038/s41572-019-0115-y. PMID: 31558729.

Zhang WZ. Why does hyperuricemia not necessarily induce gout?. Biomolecules. 2021 Feb 14;11(2):280.

Ganeshpurkar A, Saluja AK. The pharmacological potential of rutin. Saudi pharmaceutical journal. 2017 Feb 1;25(2):149-64.

Chen YS, Hu QH, Zhang X, Zhu Q, Kong LD. Beneficial effect of rutin on oxonate-induced hyperuricemia and renal dysfunction in mice. Pharmacology. 2013;92(1-2):75-83.

Sharma S, Ali A, Ali J, Sahni JK, Baboota S. Rutin: therapeutic potential and recent advances in drug delivery. Expert opinion on investigational drugs. 2013 Aug 1;22(8):1063-79.

Wu H, Wang Y, Huang J, Li Y, Lin Z, Zhang B. Rutin ameliorates gout via reducing XOD activity, inhibiting ROS production and NLRP3 inflammasome activation in quail. Biomedicine & Pharmacotherapy. 2023 Feb 1;158:114175.

Malik N, Dhiman P, Khatkar A. In silico design and synthesis of targeted rutin derivatives as xanthine oxidase inhibitors. BMC chemistry. 2019 Dec;13:1-3.

Ganeshpurkar A, Saluja A. In silico interaction of rutin with some immunomodulatory targets: a docking analysis.

Mohanraj K, Karthikeyan BS, Vivek-Ananth RP, Chand RB, Aparna SR, Mangalapandi P, Samal A. IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry A nd Therapeutics. Scientific reports. 2018 Mar 12;8(1):4329.

Yao ZJ, Dong J, Che YJ, Zhu MF, Wen M, Wang NN, Wang S, Lu AP, Cao DS. TargetNet: a web service for predicting potential drug–target interaction profiling via multi-target SAR models. Journal of computer-aided molecular design. 2016 May;30:413-24.

Kuhn M, Szklarczyk D, Franceschini A, Von Mering C, Jensen LJ, Bork P. STITCH 3: zooming in on protein–chemical interactions. Nucleic acids research. 2012 Jan 1;40(D1):D876-80.

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000 Jan 1;28(1):27-30. doi: 10.1093/nar/28.1.27. PMID: 10592173; PMCID: PMC102409.

Bartuzi D, Kaczor AA, Targowska-Duda KM, Matosiuk D. Recent Advances and Applications of Molecular Docking to G Protein-Coupled Receptors. Molecules. 2017 Feb 22;22(2):340. doi: 10.3390/molecules22020340. PMID: 28241450; PMCID: PMC6155844.

Guan L, Yang H, Cai Y, Sun L, Di P, Li W, Liu G, Tang Y. ADMET-score - a comprehensive scoring function for evaluation of chemical drug-likeness. Medchemcomm. 2018 Nov 30;10(1):148-157. doi: 10.1039/c8md00472b. PMID: 30774861; PMCID: PMC6350845.

Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A, Chen X. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Research. 2021 Jul 2;49(W1):W5-14.

Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Current opinion in rheumatology. 2010 Mar 1;22(2):165-72.

Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Therapeutic advances in musculoskeletal disease. 2016 Aug;8(4):145-59.

Martinon F, Glimcher LH. Gout: new insights into an old disease. The Journal of clinical investigation. 2006 Aug 1;116(8):2073-5.

Le MT, Shafiu M, Mu W, Johnson RJ. SLC2A9--a fructose transporter identified as a novel uric acid transporter. Nephrol Dial Transplant. 2008 Sep;23(9):2746-9. doi: 10.1093/ndt/gfn349. Epub 2008 Jul 7. PMID: 18606621; PMCID: PMC2734172.

Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu X, Janicijevic B, Smolej-Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A, Donnelly LA, Fairbanks LD, Aringer M, McKeigue PM, Ralston SH, Morris AD, Rudan P, Hastie ND, Campbell H, Wright AF. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet. 2008 Apr;40(4):437-42. doi: 10.1038/ng.106. Epub 2008 Mar 9. PMID: 18327257.

Mandal AK, Leask MP, Estiverne C, Choi HK, Merriman TR, Mount DB. Genetic and Physiological Effects of Insulin on Human Urate Homeostasis. Front Physiol. 2021 Aug 2;12:713710. doi: 10.3389/fphys.2021.713710. PMID: 34408667; PMCID: PMC8366499.

Han L, Cao C, Jia Z, Liu S, Liu Z, Xin R, Wang C, Li X, Ren W, Wang X, Li C. Epidermal growth factor gene is a newly identified candidate gene for gout. Sci Rep. 2016 Aug 10;6:31082. doi: 10.1038/srep31082. PMID: 27506295; PMCID: PMC4978989.

de Araújo ME, Franco YE, Alberto TG, Sobreiro MA, Conrado MA, Priolli DG, Sawaya AC, Ruiz AL, de Carvalho JE, de Oliveira Carvalho P. Enzymatic de-glycosylation of rutin improves its antioxidant and antiproliferative activities. Food chemistry. 2013 Nov 1;141(1):266-73.


Refbacks

  • There are currently no refbacks.